Xalkori (Crizotinib) 250mg – ALK/ROS1+ NSCLC, ALCL, and IMT Treatment

Xalkori (crizotinib) is indicated for the treatment of cancers with specific genetic alterations involving the ALK or ROS1 genes. It is used in:

• Adults with metastatic non-small cell lung cancer (NSCLC) that is ALK-positive or ROS1-positive.

• Pediatric patients (aged 1 year and older) and young adults with systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive, relapsed, or refractory.

• Adults and pediatric patients (aged 1 year and older) with inflammatory myofibroblastic tumor (IMT) that is ALK-positive, unresectable, recurrent, or refractory.

Crizotinib is an oral targeted therapy that inhibits ALK and ROS1 tyrosine kinases, helping to slow or stop cancer cell growth in tumors with these gene alterations. Dosage and duration should always be prescribed and monitored by a specialist oncologist.